From January 1, 2024 to March 22, 2024, the company has repurchased 12,614,000 shares, representing 5.44% for ¥22,153.85 million. With this, the company has completed the repurchase of 50,000,000 shares, representing 19.32% for ¥68,767.93 million under the buyback announced on November 7, 2023.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,664 JPY | +1.87% | +1.93% | +1.15% |
Apr. 25 | AstraZeneca upbeat as cancer drugs underpin sales growth | AN |
Apr. 08 | AstraZeneca hails neurological data for Ultomiris, Soliris | AN |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+1.15% | 2.32B | |
+11.20% | 8.25B | |
-25.64% | 703M | |
+29.76% | 358M | |
+3.88% | 327M | |
+5.69% | 349M | |
-6.11% | 270M | |
+15.54% | 182M | |
+26.63% | 99.29M | |
-28.33% | 63.25M |
- Stock Market
- Equities
- 6417 Stock
- News Sankyo Co., Ltd.
- Tranche Update on Sankyo Co., Ltd.'s Equity Buyback Plan announced on November 7, 2023.